Beyond Celiac Chosen by 9 Meters Biopharma as Exclusive Patient Organization to Recruit for First-Ever Phase 3 Clinical Trial

Premier Patient Recruiter for Celiac Disease Research, Beyond Celiac Taps Extensive Network to Advance Study

Go Beyond Celiac, an online patient database launched in 2017, allows its thousands of users to participate in research by sharing their celiac disease stories and experiences and learn how to become involved in research studies such as the Phase 3
Go Beyond Celiac, an online patient database launched in 2017, allows its thousands of users to participate in research by sharing their celiac disease stories and experiences and learn how to become involved in research studies such as the Phase 3
Go Beyond Celiac, an online patient database launched in 2017, allows its thousands of users to participate in research by sharing their celiac disease stories and experiences and learn how to become involved in research studies such as the Phase 3

Philadelphia, PA, Oct. 14, 2020 (GLOBE NEWSWIRE) — Beyond Celiac, the leading catalyst for a celiac disease cure in the United States, today announced it has been chosen by 9 Meters Biopharma, Inc. (Nasdaq: NMTR) as the exclusive patient organization to recruit for the first-ever Phase 3-stage clinical trial therapeutic for treatment of celiac disease. Beyond Celiac will use its unrivaled connection to the celiac disease community and its powerful online patient database to recruit participants for the study of larazotide acetate, which aims to address leaky gut in celiac disease.

“We really listen to our community’s wants and needs. Because of our extensive connection to the people and commitment to connecting researchers with our community, Beyond Celiac has become the partner of choice for leading biotechnology and pharmaceutical companies such as 9 Meters,” said Beyond Celiac CEO Alice Bast. “This is the furthest a celiac disease clinical trial has gone, and it’s an exciting opportunity for our organization to play a vital role in fulfilling its promise.”

9 Meters Biopharma is evaluating larazotide acetate for celiac disease patients who continue to experience gastrointestinal symptoms while following a gluten-free diet. Designed to tighten junctions between intestinal cells, larazotide acetate would act like shoelaces to help restore leaky junctions to a normal state and would be used in addition to the gluten-free diet. It is being tested at more than 100 clinical sites, with a goal of 525 study participants. Results are expected by the end of 2021.

By partnering with Beyond Celiac for recruitment, 9 Meters Biopharma now has access to the power of Go Beyond Celiac, a secure online patient database with thousands of users who share their celiac disease stories and experiences with researchers and seek to become involved in studies.

“Our conservative estimate is that our celiac disease program is at least two years ahead of everyone else’s,” said John Temperato, president and CEO of 9 Meters Biopharma. “Beyond Celiac is going to help us across the finish line in developing the effective treatments that celiac patients deserve.”

Celiac disease is a serious genetic autoimmune disorder that affects an estimated 1 in 133 Americans, more than half of whom are still undiagnosed. The disease causes damage to the small intestine, resulting in debilitating symptoms, and if left untreated, can lead to serious long-term health problems including infertility and some types of cancer.

 

About Beyond Celiac

Founded in 2003,

Vida Health Chosen as Virtual Chronic Disease Provider for Vitality’s Gateway Flex Marketplace

Vida’s chronic condition management, stress management, weight loss and lifestyle programs will be offered on the first-of-its-kind benefits marketplace

Vida Health has been selected as a preferred virtual health provider for Vitality’s new Gateway Flex. As employers face rising costs of employee benefits and the changes brought on by the pandemic, Gateway Flex offers a new way of boosting health and wellness engagement by offering more relevant choices to employees to meet their specific needs.

Through the first-of-its-kind platform, employers select a list of partners that will be most impactful in meeting their employees’ diverse health needs. Employees are then able to select the services they need and can use employer-allocated funds to purchase services of their choice.

As a preferred partner, Vida Health will offer a number of clinically validated programs for users to choose from. The programs include weight loss, stress management, chronic condition management, tobacco cessation, exercise, nutrition, sleep, resilience, and prediabetes.

“Vida has a proven track-record of achieving industry-leading outcomes for its users,” said Tal Gilbert, CEO, Vitality USA. “We were very selective about which vendors we offered as part of Gateway Flex and the sustained behavior change and lasting outcomes Vida’s virtual solution provides were a perfect fit for our member organizations.”

“We’re proud to be participating in this innovative new program from Vitality,” said Vida Health Founder and CEO Stephanie Tilenius. “The only way to solve America’s health problem is by helping people to live healthier lives — one person at a time. The additional people who now have access to Vida through this partnership help us move closer to our goal of eradicating chronic illness in America.”

About Vida Health

Vida Health is a leading virtual care platform that was designed from the ground up to treat multiple chronic health conditions simultaneously, through a balance of machine learning that personalizes each person’s treatment and a human connection with real life health coaches and therapists who bring the empathy and accountability people need to reach their goals. Vida Health’s services are delivered through a mobile platform that supports individuals in preventing, managing and reversing chronic conditions such as pre-diabetes, diabetes, hypertension, obesity, depression, anxiety, etc. The platform integrates deep individual expert care with data-driven technology and remote monitoring to deliver best-in-class health outcomes and cost savings to employers and health plans. To-date, some of the largest nationwide health plans and employers have benefited from Vida’s unique offering.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201013005296/en/

Contacts

Connor Jones
Connor.Jones@Vida.com

Source Article